Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects



Rating:

Share or cite this content

Citations should be made in the following way:
B. Guidetti (Rotterdam, Netherlands), A. Bos (Rotterdam, Netherlands), E. Van Der Wiel (Rotterdam, Netherlands), I. Meneghelli (Verona, Italy), M. Van Der Eerden (Rotterdam, Netherlands), H. Tiddens (Rotterdam, Netherlands), S. Volpi (Verona, Italy), H. Janssens (Rotterdam, Netherlands). Targeting Antibiotics to Pseudomonas aeruginosa in Small airways (TAPAS) in patients with Cystic Fibrosis. 3372

Member's Comments

No comment yet.

Related content which might interest you: Microevolution of pseudomonas aeruginosa in cystic fibrosis lungs Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Host specificity of pseudomonas aeruginosa isolates from patients with cystic fibrosis and patients from different clinical backgrounds Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Temperate bacteriophages of pseudomonas aeruginosa as markers of bacterial adaptation in CF and non-CF bronchiectasis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Adaptation of prevotella during acute infectious pulmonary exacerbation Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Results of Tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas Aeruginosa colonization: Real Life Management Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Atorvastatin as novel treatment in bronchiectasis patients colonized with pseudomonas aeruginosa Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Should pseudomonas aeruginosa be the main target in bronchiectasis? Source: International Congress 2016 – Monitoring comorbidities Year: 2016